Leerink Partnrs Has Negative Forecast for COGT Q2 Earnings

Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) - Equities research analysts at Leerink Partnrs cut their Q2 2025 EPS estimates for Cogent Biosciences in a note issued to investors on Monday, July 14th. Leerink Partnrs analyst A. Berens now anticipates that the technology company will post earnings per share of ($0.65) for the quarter, down from their previous estimate of ($0.63). The consensus estimate for Cogent Biosciences' current full-year earnings is ($2.42) per share. Leerink Partnrs also issued estimates for Cogent Biosciences' Q3 2025 earnings at ($0.54) EPS, Q4 2025 earnings at ($0.56) EPS and FY2026 earnings at ($1.47) EPS.

Other equities analysts have also issued research reports about the stock. Needham & Company LLC reissued a "hold" rating on shares of Cogent Biosciences in a research report on Tuesday, June 17th. Leerink Partners lifted their price target on shares of Cogent Biosciences from $16.00 to $18.00 and gave the company an "outperform" rating in a research report on Monday, July 7th. Jefferies Financial Group lifted their price target on shares of Cogent Biosciences from $23.00 to $28.00 and gave the company a "buy" rating in a research report on Monday, July 7th. Guggenheim reissued a "buy" rating and issued a $17.00 price target on shares of Cogent Biosciences in a research report on Tuesday, July 8th. Finally, Wedbush reissued a "neutral" rating and issued a $10.00 price target on shares of Cogent Biosciences in a research report on Monday, June 30th. Three investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $18.70.

Cogent Biosciences Price Performance

COGT traded up $0.29 during midday trading on Thursday, hitting $12.49. 3,679,739 shares of the company's stock traded hands, compared to its average volume of 1,630,387. The company has a market cap of $1.42 billion, a PE ratio of -6.79 and a beta of 1.88. The stock's fifty day simple moving average is $7.22 and its 200-day simple moving average is $6.97. Cogent Biosciences has a one year low of $3.72 and a one year high of $12.95.

Cogent Biosciences (NASDAQ:COGT - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The technology company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.04.

Institutional Investors Weigh In On Cogent Biosciences

A number of institutional investors have recently bought and sold shares of COGT. Balyasny Asset Management L.P. raised its stake in shares of Cogent Biosciences by 8.8% in the 4th quarter. Balyasny Asset Management L.P. now owns 20,805 shares of the technology company's stock valued at $162,000 after buying an additional 1,687 shares in the last quarter. Teacher Retirement System of Texas boosted its stake in shares of Cogent Biosciences by 15.4% in the 4th quarter. Teacher Retirement System of Texas now owns 17,983 shares of the technology company's stock valued at $140,000 after purchasing an additional 2,396 shares in the last quarter. Arizona State Retirement System boosted its stake in shares of Cogent Biosciences by 18.0% in the 1st quarter. Arizona State Retirement System now owns 20,567 shares of the technology company's stock valued at $123,000 after purchasing an additional 3,142 shares in the last quarter. MetLife Investment Management LLC boosted its stake in shares of Cogent Biosciences by 6.3% in the 4th quarter. MetLife Investment Management LLC now owns 56,750 shares of the technology company's stock valued at $443,000 after purchasing an additional 3,382 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Cogent Biosciences by 6.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 62,275 shares of the technology company's stock valued at $377,000 after purchasing an additional 3,693 shares in the last quarter.

Insider Activity

In related news, Director Fairmount Funds Management Llc acquired 2,777,777 shares of the stock in a transaction dated Thursday, July 10th. The shares were acquired at an average price of $9.00 per share, for a total transaction of $24,999,993.00. Following the completion of the purchase, the director owned 9,003,418 shares in the company, valued at approximately $81,030,762. The trade was a 44.62% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 7.29% of the company's stock.

Cogent Biosciences Company Profile

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.